This trial is active, not recruiting.

Condition cervical cancer
Treatment 18f-fluorodeoxyglucose positron emission tomography
Phase phase 3
Sponsor Chang Gung Memorial Hospital
Collaborator National Science Council, Taiwan
Start date January 2002
End date December 2007
Trial size 200 participants
Trial identifier NCT00146458, CTRP024, NSC 92-2314-B-182A-084


The objective of this study is to determinate whether the adding of FDG-PET is helpful in the treatment of advanced cervical cancer with concurrent chemoradiation.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose diagnostic

Primary Outcomes

The difference of disease-free-survival and overall-survival with/ without FDG-PET at two years after treatment
time frame:

Secondary Outcomes

The incidence of additional extra-pelvic tumor metastasis detected by FDG-PET study, and its influence on the design of appropriate radiotherapy treatment
time frame:

Eligibility Criteria

Female participants of any age.

Inclusion Criteria: - Newly diagnosed cervical cancer clinical stage FIGO I –IVA - Histologically proven cervical carcinoma (including histologic types of squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma, adenoid cystic carcinoma, lymphoepithelial-like carcinoma and malignant mixed mullerian tumor) - Presence of at least one enlarged pelvic lymph node (>=1.0 cm in its maximal dimension), or group of small pelvic nodes (size <1 cm), and without suspicious para-aortic lymph node metastasis or any lesion outside the pelvis by conventional MRI or CT study - Karnofsky performance scale >=60 - Available for concurrent chemoradiation therapy of curative intent Exclusion Criteria: - Cervical tumor with histologic diagnosis of verrucous carcinoma or small cell carcinoma - Other serious illness or medical condition which would interfere with extended field irradiation or chemotherapy - Past or current history of malignancy, except for curatively treated non-melanoma skin cancer - Patients not suitable to receive PET study either by technical or psychological reasons - Patients who are judged to be noncompliant to treatment or not accessible for follow up

Additional Information

Official title A Phase III Randomized Trial of FDG-PET in the Management of Advanced Cervical Cancer With Enlarged Pelvic Lymph Node on MRI Image
Principal investigator Chien-Sheng Tsai, M.D.
Description Concurrent radiotherapy and chemotherapy is the standard treatment for locally advanced cervical cancer. The radiation field should be adjusted according to the extension of disease, especially the presence of metastatic lymph nodes. At present, CT/ MRI have been applied for the detection of enlarged lymph nodes, as the reference of radiation field. However, not infrequently, a small-sized lymph node on CT/MRI may be metastatic while an enlarged node may be resulted from reactive hyperplasia. Unlike CT/ MRI, 18F-FDG positron emission tomography (FDG-PET) provides a novel means of imaging malignancy and could differentiate benign tumor from malignancy by functional assessment. Recent studies demonstrated higher accuracy of FDG-PET scan for the evaluation of metastasis in patients with several types of cancers when compared with CT scan or MRI. But, only a few reports concerned the usefulness of FDG-PET in cervical carcinoma. Our hypothesis is that adding FGD-PET study to a thorough MRI can provide better staging, especially on the identification of metastatic pelvic or para-aortic lymph nodes. In addition, this whole body scan may also detect occult distant metastases that are not detectable by standard workup. Our initial result of a phase II study---"A Preliminary Report of Using FDG-PET to Detect Extra-pelvic Lesions in Cervical Cancer Patients with Enlarged Pelvic Lymph Nodes Shown on MRI/CT Images” indicated that FDG-PET helped to detect occult or small metastatic lesions, and resulted in a change of radiation treatment plan. Nevertheless, for high-risk group patients, distant metastasis still occurred in a short period after treatment. Therefore, it is also our question that whether the enhancement of detection provided by FDG-PET can be translated into improvement of final overall survival. To answer these questions, the Gynecologic Oncology Study Group in Chang Gung Memorial Hospital has designed a phase III clinical study. Patients with enlarged pelvic lymph node detected on MRI imaging are enrolled and randomized into two groups before the initiation of concurrent chemoradiation.
Trial information was received from ClinicalTrials.gov and was last updated in September 2006.
Information provided to ClinicalTrials.gov by Chang Gung Memorial Hospital.